MTOR and acute myeloid leukemia: Numerous studies have demonstrated that drugs that inhibit the mechanistic target of rapamycin (mTOR) and activate AMP-kinase (AMPK) have beneficial effects in promoting differentiation and blocking proliferation of different cancers, i.e., in hematological malignancies such as acute myeloid leukemia (AML) [56].